Montreal Heart Institute Colcorona Study receives grant from the COVID-19 Therapeutics Accelerator via the Bill & Melinda Gates Foundation to investigate cheap, readily available drug
Clinical study evaluating colchicine as a potential treatment to reduce inflammatory conditions seen in patients with COVID-19

May 12, 2020 08:50 ET | Source: Montreal Heart Institute
multilang-release


MONTREAL, May 12, 2020 (GLOBE NEWSWIRE) -- The Montreal Heart Institute (MHI) Research Center today announced a 3-million-dollar grant from the COVID-19 Therapeutics Accelerator for its innovative ColCorona COVID-19 clinical trial. This contact-less at home study is investigating colchicine as a potential treatment to reduce severe inflammatory conditions associated with COVID-19, slow disease progression, and save patient lives.

As this low-cost common gout drug presents itself as a potential treatment to fight coronavirus, this recognition by the Foundation will enable MHI to bring this research to a greater number of people affected by COVID-19, especially in areas where the population is more vulnerable due to health and economic inequities.

The COVID-19 Therapeutics Accelerator is an initiative launched by the Bill & Melinda Gates Foundation, Wellcome, and Mastercard, with funding from an array of public and philanthropic donors, to speed up the response to the COVID-19 pandemic by funding the identification, assessment, development and scale up of treatments.

“ColCorona exemplifies how we can look to bring scientific breakthroughs in a time- and cost-effective manner to patients by repurposing older drugs,” said Dr. Jean-Claude Tardif, Director of the Research Center at MHI, Professor of Medicine at the University of Montreal, and ColCorona primary investigator. “We are at a critical juncture in searching for a treatment for patients with coronavirus and I, along with my colleagues involved in ColCorona around the world, are hopeful that colchicine will prove to have a positive effect on the serious inflammation seen in COVID-19, potentially keeping patients out of the ICU and ultimately saving lives.”

The hypothesis is that colchicine may prevent the phenomenon of major inflammatory storm responsible for severe complications seen in patients with COVID-19. This is one of the few current studies of COVID-19 infection in which non-hospitalized individuals can participate. The clinical study is contact-less and is done from home. MHI is currently assessing several sites and support associations in which assistance for patients wanting to join the study can be provided. Anyone interested in receiving more information or wanting their association to be considered can call 1 877 536 6837 to find out more.

The patient eligibility criteria for the study are:

Diagnosis of COVID-19
Be 40 years and over
Not hospitalized
Be willing to take the drug or placebo daily for 30 days
Be willing to participate in two follow-up calls by phone or videoconference.
Women of child bearing potential who do not take contraceptives, those who are pregnant, or those who are breastfeeding are not eligible for the trial. Physicians with patients, or people with a positive COVID-19 diagnosis who are interested in participating in the clinical study, can call the hotline any time at 1-877-536-6837.

For more information on COLCORONA clinical trial, visit www.colcorona.net.

COLCORONA is coordinated by the Montreal Health Innovations Coordinating Center (MHICC), funded by the Government of Quebec, and supported by Pharmascience, CGI and the U.S. National Institutes of Health (NIH).

COVID-19 Therapeutics Accelerator donors include the Bill & Melinda Gates Foundation, Wellcome, Mastercard, U.K. Department for International Development, Chan Zuckerberg Initiative, Michael & Susan Dell Foundation, Avast, Zhang Yiming, Alwaleed Philanthropies, EQT and Madonna.

About Colchicine
Colchicine is a generic, orally administered anti-inflammatory medication that is currently indicated for the management of pericarditis, gout, and familial Mediterranean fever. It is not a non-steroidal anti-inflammatory medicine. Colchicine was recently studied in the COLCOT study (published in the New England Journal of Medicine), which compared colchicine 0.5mg daily to placebo on top of standard of care in preventing ischemic cardiovascular events in patients with a recent myocardial infarction (MI).

About ColCorona
COLCORONA is a randomized, double-blind, placebo-controlled study. It was initiated by Dr. Jean-Claude Tardif, Director of the MHI Research Center and Professor of Medicine at the University of Montreal and aims to determine if colchicine may prevent the phenomenon of major inflammatory storm observed in adults suffering from serious complications linked to COVID-19. The clinical trial requires the recruitment of 6,000 patients who meet all the inclusion criteria and none of the exclusion criteria. Patients will be randomly assigned to either colchicine or a placebo (1:1 ratio) for 30 days. Evaluations by phone or videoconference will then take place 15 and 30 days after the randomization. The sample size will allow researchers to detect if there is a reduction of at least 25% in the risk of events, taking into account a 7% event rate in the placebo group. The study will be monitored by a data monitoring committee (DMC) that includes experienced clinical researchers.

About the Montreal Heart Institute
Founded in 1954, the Montreal Heart Institute constantly aims for the highest standards of excellence in the cardiovascular field through its leadership in clinical and basic research, ultra-specialized care, professional training, and prevention. It houses the largest research center in Canada, the largest cardiovascular prevention center and the largest cardiovascular genetics center in the country. The Institute is affiliated with the University of Montreal and has more than 2,000 employees, including 245 doctors and more than 85 researchers.

About the Montreal Health Innovations Coordinating Center (MHICC):
The Montreal Health Innovations Coordinating Center (MHICC) is a leading academic clinical research organization and an integral part of the Montreal Heart Institute (MHI). The MHICC possesses an established network of collaborators in over 4,500 clinical sites in more than 30 countries. It has specific expertise in precision medicine, low-cost high-quality clinical trials, and drug repurposing.

About Pharmascience
Founded in 1983, Pharmascience Inc. is the largest pharmaceutical employer in Quebec. With its head office located in Montreal and its 1,500 employees, Pharmascience Inc. is a private, full-service pharmaceutical company with deep roots in Canada, and whose global reach is growing, in part thanks to the distribution of its products in more than 60 countries. Ranked 56th among the top 100 Canadian investors in research and development (R&D) thanks to $ 43 million investment in 2018, Pharmascience Inc. is the 4th largest manufacturer of over-the-counter generic drugs in the country. www.pharmascience.com

About CGI
Founded in 1976, CGI is one of the world's largest information technology (IT) and management consulting firms. From hundreds of locations around the world, CGI offers a complete portfolio of services and solutions: strategic IT and management consulting services, systems integration services, intellectual property solutions as well as IT and business process management services in delegated mode. www.cgi.com/canada

Note to media: ColCorona Clinical Trial is available in Montreal, New York Tri State Area (NYU Langone), New Jersey and Connecticut, California (UCSF), Madrid (Spain), British Columbia, Ontario and Alberta. Lead investigators in each city are available for interviews.

Source: Montreal Heart Institute

Media inquiries:

For Montreal Heart Institute:
Camille Turbide
Camille.turbide@gmail.com
+1 514 755 5354

https://www.globenewswire.com/news-release/2020/05/12/2031943/0/en/Montreal-Heart-Institute-Colcorona-Study-receives-grant-from-the-COVID-19-Therapeutics-Accelerator-via-the-Bill-Melinda-Gates-Foundation-to-investigate-cheap-readily-available-drug.html

Quebec researchers say they have found an effective drug to fight COVID-19

The Canadian Press Staff
Published Saturday, January 23, 2021 7:51AM EST
https://montreal.ctvnews.ca/quebec-researchers-say-they-have-found-an-effective-drug-to-fight-covid-19-1.5279310

MONTREAL -- A team of researchers from the Montreal Heart Institute believes they have found an effective weapon against COVID-19: colchicine, an oral tablet already known and used for other diseases.

For Dr. Jean-Claude Tardif, who led the study, this is a "major scientific discovery" and colchicine is the first "effective oral drug to treat out-of-hospital patients."

"To be able to offer this, from Quebec, and for the planet, we are very happy," said Tardif.

The ColCorona study involved 4,159 patients whose diagnosis of COVID-19 had been proven by a nasopharyngeal test (PCR).

Complete coverage at CTVNews.ca/coronavirus
Coronavirus newsletter sign-up: Get The COVID-19 Brief sent to your inbox

Analysis of the study found that colchicine resulted in reductions in hospitalizations by 25 per cent, the need for mechanical ventilation by 50 per cent, and deaths by 44 per cent.

"This is the first hope for patients who have COVID, who are worried and who hope that they will not have complications, there were no tablets that could be taken by mouth and reduce the risks," said Tardif.

Doctor Tardif believes that prescribing the drug could help reduce congestion in hospitals quickly and reduce health-care costs here as elsewhere.

"Our study showed the effectiveness of treatment using colchicine to prevent the phenomenon of the major inflammatory storm and reduce complications related to COVID-19," said Tardif.

Colchicine could be used very quickly to treat people with COVID-19, the researcher says.

"Colchicine is old as it is, we've been treating gout with it for hundreds of years, so it's available in pharmacies, so any doctor tomorrow who reads this can definitely decide to prescribe if he wants."

On Friday evening, Premier Francois Legault called the study "big news" on social networks.

In the spring, Legault said the Colcorona study was one of the largest studies in the world to fight the virus.

The randomized, double-blind, placebo-controlled study was deployed in Canada, the United States, Europe, South America and South Africa.

"It was a double-blind study, meaning neither the patient, nor the team that ran the study including me, knew whether the patient was taking the placebo or the drug, there was just a group, independent from us, which was aware," explained Tardif.

"We are very proud of the work accomplished, it is a clinically convincing result," he said adding that he assembled a spectacular team from all over Quebec including microbiologists, intensivists, statisticians, computer scientists and epidemiologists,

The Centre de Coordination des Essais Cliniques de Montréal (MHICC) of the Montreal Heart Institute coordinated the study.

-- this report by The Canadian Press was first published Jan. 23, 2021.

https://montreal.ctvnews.ca/quebec-researchers-say-they-have-found-an-effective-drug-to-fight-covid-19-1.5279310

Like the USA.

Sorry to look stupid, but what is "8020"?

Happy Easter to all.

Commercial plastics-to-fuel plant receives financing

Posted on April 17, 2019
by Colin Staub

Laptop and financial documents on a desk with a business team in the background.Backers of a plastics-to-fuel project in Indiana announced they are preparing to break ground on a $260 million commercial-scale facility.


Brightmark Energy and RES Polyflow, which is now a subsidiary of Brightmark, announced the development April 11. The financing agreement brings the plastics-to-fuel industry one step closer to proving itself at a commercial level. Groundbreaking on the facility, the first of its kind in the U.S., is scheduled for next month.

RES Polyflow has been working to develop a full-scale facility since at least 2015, although the investment figure has grown significantly since then. When first announced, the facility anticipated a $90 million price tag.

The processing details of the facility remain similar to its initial plan: The plant will process 100,000 tons of mixed plastic into more than 18 million gallons per year of ultra-low-sulfur diesel and naphtha blend stocks, which are used in the production of new plastic. The facility will also produce six million gallons per year of commercial-grade wax, also used in plastic production.

“We are excited about the market’s confidence in the validity of this technology to economically convert single-use plastics for new uses,” Brightmark CEO Bob Powell said in the announcement.

Referred to as a conversion process, plastics-to-fuel falls under the umbrella of chemical recycling, which involves changing the chemistry of scrap plastics to make new products, rather than shredding and melting plastic for later molding. The sector has been working to prove itself over the past several years. Plastics Recycling Update previously interviewed RES Polyflow about the industry’s development and spoke with Brightmark Energy about the company’s interest in the chemical recycling sector.

Of course, they can sell rights to giants and they are!

Big giants.

I did a wee search on waste plastic and catalysts, Google is great:

Search term:
"aluminum oxide or calcium hydroxide catalysts for waste plastic to oil conversion"
https://www.google.com/search?q=aluminum+oxide+or+calcium+hydroxide+catalysts+for+waste+plastic+to+oil+conversion&oq=aluminum+oxide+or+calcium+hydroxide+catalysts+for+waste+plastic+to+oil+conversion&aqs=chrome..69i57.46566j0j7&sourceid=chrome&ie=UTF-8

Very enlightening.

Googles time spent:
About 431,000 results (0.69 seconds)

Just imagine what they could dig up in, say, 5 minutes or so!!!!!

Inovio Achieves Third Cancer Indication Milestone for MEDI0457 Phase 2 Development

PLYMOUTH MEETING, Pa., April 8, 2019 -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that it achieved a third indication milestone from AstraZeneca resulting from dosing a patient in a Phase 2 combination trial evaluating MEDI0457 (formerly called INO-3112) in combination with durvalumab targeting cervical, anal, penile, and vulvar cancers associated with the human papilloma virus (HPV). The milestone achievement for this multi-indication trial is the third MEDI0457-related Phase 2 milestone from AstraZeneca; two previous milestone payments resulted from initiating Phase 2 combination trials targeting head and neck and cervical cancers. Financial arrangements were not disclosed.
.....

https://www.prnewswire.com/news-releases/inovio-achieves-third-cancer-indication-milestone-for-medi0457-phase-2-development-300825576.html

Yup.

Anyone know if aluminum oxide or calcium hydroxide are well known catalysts?

Google?

Let's check:
https://patents.google.com/patent/US20060009352
https://pubchem.ncbi.nlm.nih.gov/compound/aluminum_oxide

Catalysts:
Claim 8:
aluminum oxide or calcium hydroxide

http://brevets-patents.ic.gc.ca/opic-cipo/cpd/eng/patent/2879973/images.html?page=12&frenchDocType=Poursuite-Amendment&englishDocType=Prosecution-Amendment&modificationDate=20171201&scale=25&rotation=0&type=basic_search&objectName=A1001001A18C12B14030E82082&numPages=47&query=bordynuik&start=1&num=50

Claims:
http://brevets-patents.ic.gc.ca/opic-cipo/cpd/eng/patent/2879973/images.html?page=11&frenchDocType=Poursuite-Amendment&englishDocType=Prosecution-Amendment&modificationDate=20171201&scale=25&rotation=0&type=basic_search&objectName=A1001001A18C12B14030E82082&numPages=47&query=bordynuik&start=1&num=50

Claims:

http://brevets-patents.ic.gc.ca/opic-cipo/cpd/eng/patent/2879973/images.html?page=11&frenchDocType=Poursuite-Amendment&englishDocType=Prosecution-Amendment&modificationDate=20171201&scale=25&rotation=0&type=basic_search&objectName=A1001001A18C12B14030E82082&numPages=47&query=bordynuik&start=1&num=50

http://brevets-patents.ic.gc.ca/opic-cipo/cpd/eng/patent/2879973/images.html?page=12&frenchDocType=Poursuite-Amendment&englishDocType=Prosecution-Amendment&modificationDate=20171201&scale=25&rotation=0&type=basic_search&objectName=A1001001A18C12B14030E82082&numPages=47&query=bordynuik&start=1&num=50

http://brevets-patents.ic.gc.ca/opic-cipo/cpd/eng/patent/2879973/images.html?page=13&frenchDocType=Poursuite-Amendment&englishDocType=Prosecution-Amendment&modificationDate=20171201&scale=25&rotation=0&type=basic_search&objectName=A1001001A18C12B14030E82082&numPages=47&query=bordynuik&start=1&num=50

http://brevets-patents.ic.gc.ca/opic-cipo/cpd/eng/patent/2879973/images.html?page=14&frenchDocType=Poursuite-Amendment&englishDocType=Prosecution-Amendment&modificationDate=20171201&scale=25&rotation=0&type=basic_search&objectName=A1001001A18C12B14030E82082&numPages=47&query=bordynuik&start=1&num=50

Inovio's Ebola Vaccine Delivered Intradermally Demonstrates 100% Immunogenicity in a Clinical Study Published in The Journal of Infectious Diseases

PLYMOUTH MEETING, Pa., March 21, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (INO) announced today that its Ebola vaccine, INO-4201, was safe, tolerable, and generated strong T cell and antibody responses. This Phase 1 data was published in The Journal of Infectious Diseases https://c212.net/c/link/?t=0&l=en&o=2409747-1&h=3108008505&u=https%3A%2F%2Facademic.oup.com%2Fjid%2Fadvance-article-abstract%2Fdoi%2F10.1093%2Finfdis%2Fjiz132%2F5395966&a=The+Journal+of+Infectious+Diseases and further supports the advancement of the intradermal delivery platform for emerging infectious diseases. Significantly, the study demonstrated that intradermal (skin) administration with Inovio's CELLECTRA® delivery device resulted in 100% of evaluable subjects generating antigen-specific antibody responses that persisted for more than one year in most subjects and generated T cell responses equivalent to or better than the group that received intramuscular delivery. The published data further validates the safety, potency, and product stability advantages of Inovio's vaccine and immunotherapy platform.

https://finance.yahoo.com/news/inovios-ebola-vaccine-delivered-intradermally-131100376.html

"PEN Comeback" indicates a comeback of some sort is in the works. What it entails and who is involved remains to be revealed.

Their patent pending process was never patented!

http://www.plastic2oil.com/site/patent-pending

Oh well, it passes the time.

When they cure cancer and viral disease it will all be clear.

Eh?

GOOGLE:

https://www.bizapedia.com/mi/pen-comeback-llc.html

https://www.marketscreener.com/PEN-INC-17632470/news/PEN-INC-Entry-into-a-Material-Definitive-Agreement-Unregistered-Sale-of-Equity-Securities-Chang-27445736/

INO is a start up and has no saleable product. The only way they can make money is to sell something. The future awaits. What will it reveal?

THAT IS THE QUESTION!

My crystal ball says $300.

Why Inovio Pharmaceuticals Stock Broke Down in February
Motley Fool
George Budwell, The Motley Fool

March 6, 2019

What happened
Shares of Inovio Pharmaceuticals (NASDAQ: INO), a clinical-stage immunotherapy company, fell by an unsightly 26% last month, according to data from S&P Global Market Intelligence. What event triggered this sell-off?

Inovio's stock fell in response to a convertible debt offering halfway through the month. Investors apparently weren't pleased with either the terms of the debt offering or the fact that the initial purchasers decided not to buy the full allotment of additional notes.

So what
Inovio was attempting to raise $82.1 million in net proceeds with this convertible debt offering. However, the company walked away with only $75.8 million in total. While market conditions can dictate the interest from buyers in these types of offerings, Inovio's inability to sell the full allotment of additional notes seems to indicate that Wall Street isn't overly optimistic about the company's future. Biotech stocks, after all, are enjoying a strong resurgence this year and this capital raise wasn't particularly large for a company that sports a late-stage clinical asset.

Now what
Capital raises -- even ones on unfavorable terms -- are part and parcel of the clinical-stage investing landscape. That's an inescapable drawback of investing in these types of equities. Thus, the market's overtly negative reaction to this offering is probably a bit overdone at this point.

What really matters from an investing standpoint is that Inovio is now less than two years out from reporting top-line data for its lead vaccine candidate, VGX-3100. VGX-3100 is presently in a late-stage trial as a potential treatment for HPV-related cervical pre-cancer.

If this experimental vaccine scores a win in this ongoing trial, Inovio's share price should quickly return to form and then some. A failure, by contrast, will undoubtedly be greeted by another round of heavy selling. Given this binary outcome, capital raises shouldn't necessarily be a major point of concern for retail investors at this stage. The bigger deal is that Inovio has the funds necessary to complete its first-ever late-stage trial.

https://finance.yahoo.com/news/why-inovio-pharmaceuticals-stock-broke-134200815.html

PyroGenesis Ships First Batch of Specialty 3D Metal Powder Under Contract to Government Entity

GlobeNewswire•March 5, 2019

MONTREAL, March 05, 2019 (GLOBE NEWSWIRE) -- PyroGenesis Canada Inc. (http://pyrogenesis.com) (PYR.V) (PYRNF) (8PY.F), a TSX Venture 50® high-tech company, (the "Company", the “Corporation” or "PyroGenesis") that designs, develops, manufactures and commercializes plasma atomized metal powder, plasma waste-to-energy systems and plasma torch products, announces today that, further to its Press Release dated December 17th, 2018, wherein a contract for specialty metal powder to a government entity (the “Client”) was announced, the Company has shipped its first batch of specialty 3D metal powder to the Client, the name, origin, amount, and type of powder are not permitted to be disclosed.

As previously announced, under this contract, PyroGenesis is to produce specialty reactive metal powder using its plasma atomization system. The Client intends to use this powder for confidential purposes. Follow-on orders are expected.

The Company is shipping according to the schedule dictated by the Client and, as such, the order is being shipped in several pre-determined batches. All shipments will be completed within eight (8) weeks.

“This powder delivery represents another significant milestone for PyroGenesis Additive. We know of no other process which can produce this material better. Of note, this is the first powder produced utilizing the Company’s new plasma-based production process, at a production rate superior to any published plasma atomization process,” said Mr. Massimo Dattilo, Vice President of PyroGenesis Additive. “It is our first volume order for delivery of a 3D powder which is not a titanium alloy, however is reactive. This clearly underscores the versatility of our Plasma Atomization process proving, once again, that it lends itself well to producing best-in-class powders for the Additive Manufacturing industry.”

Separately, the Company is also pleased to announce the receipt of an export permit to start shipping titanium powder to France.

About PyroGenesis Canada Inc.

PyroGenesis Canada Inc., a TSX Venture 50® high-tech company, is the world leader in the design, development, manufacture and commercialization of advanced plasma processes and products. We provide engineering and manufacturing expertise, cutting-edge contract research, as well as turnkey process equipment packages to the defense, metallurgical, mining, advanced materials (including 3D printing), oil & gas, and environmental industries. With a team of experienced engineers, scientists and technicians working out of our Montreal office and our 3,800 m2 manufacturing facility, PyroGenesis maintains its competitive advantage by remaining at the forefront of technology development and commercialization. Our core competencies allow PyroGenesis to lead the way in providing innovative plasma torches, plasma waste processes, high-temperature metallurgical processes, and engineering services to the global marketplace. Our operations are ISO 9001:2015 certified, and have been since 1997.

PyroGenesis is a publicly-traded Canadian Corporation on the TSX Venture Exchange (Ticker Symbol: PYR) and on the OTCQB Marketplace. For more information, please visit www.pyrogenesis.com"

PyroGenesis Canada Inc., a TSX Venture 50® high-tech company, is the world leader in the design, development, manufacture and commercialization of advanced plasma processes and products. We provide engineering and manufacturing expertise, cutting-edge contract research, as well as turnkey process equipment packages to the defense, metallurgical, mining, advanced materials (including 3D printing), oil & gas, and environmental industries. With a team of experienced engineers, scientists and technicians working out of our Montreal office and our 3,800 m2 manufacturing facility, PyroGenesis maintains its competitive advantage by remaining at the forefront of technology development and commercialization. Our core competencies allow PyroGenesis to lead the way in providing innovative plasma torches, plasma waste processes, high-temperature metallurgical processes, and engineering services to the global marketplace. Our operations are ISO 9001:2015 certified, and have been since 1997. PyroGenesis is a publicly-traded Canadian Corporation on the TSX Venture Exchange (Ticker Symbol: PYR) and on the OTCQB Marketplace. For more information, please visit www.pyrogenesis.com

This press release contains certain forward-looking statements, including, without limitation, statements containing the words "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect", "in the process" and other similar expressions which constitute "forward- looking information" within the meaning of applicable securities laws. Forward-looking statements reflect the Corporation's current expectation and assumptions and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, our expectations regarding the acceptance of our products by the market, our strategy to develop new products and enhance the capabilities of existing products, our strategy with respect to research and development, the impact of competitive products and pricing, new product development, and uncertainties related to the regulatory approval process. Such statements reflect the current views of the Corporation with respect to future events and are subject to certain risks and uncertainties and other risks detailed from time-to-time in the Corporation's ongoing filings with the securities regulatory authorities, which filings can be found at www.sedar.com, or at www.otcmarkets.com. Actual results, events, and performance may differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements. The Corporation undertakes no obligation to publicly update or revise any forward- looking statements either as a result of new information, future events or otherwise, except as required by applicable securities laws.

Neither the TSX Venture Exchange, its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) nor the OTCQB accepts responsibility for the adequacy or accuracy of this press release.

SOURCE PyroGenesis Canada Inc.

For further information please contact: Clémence Bertrand-Bourlaud, Marketing Manager/Investor Relations, Phone: (514) 937-0002, E-mail: ir@pyrogenesis.com

RELATED LINKS: http://www.pyrogenesis.com/

https://finance.yahoo.com/news/pyrogenesis-ships-first-batch-specialty-133500343.html

News is good; a money making drug on the market is even better.

Inovio's tech:

https://www.inovio.com/technology

Yes. So few public supported efforts succeed it gives the stock market a bad rep - well deserved.

I bet Bernie Sanders agrees.

The future according to Gates at MIT:

Basically - Inovio.
"Personalized cancer vaccines"

Ref:
https://www.cnbc.com/2019/03/01/bill-gates-for-mit-technology-review-tech-that-will-change-the-world.html

Do the math!

One is known and valued by the company they keep.

OSCI associates with:

Stapp
Stonger
Friedman
Erhard


All SEC/FBI concerns.

Trust me.

Easy - find suckers. Tell them they will be patented....soon.

That's why the stock market exists - to sell stock to get money which is used to make more money.

I know it sounds goofy but it seems to work once in a blue moon.

I really think that a better system would be for the government to assess the abilty and worthiness of a project first, give those worthy the money, and get paid back when the thing succeeds. That way the people don't get screwed.

Call it socialist capitalism!

Any company able to raise $67 million for FDA testing looks like a winner to me!

You can't always be right....or wrong.

Just most of the time.

Inovio will b good for family.

Trust me!

Not so ignorant as those whose lives they may well save some day!

Please report back how that went.

I expect the buyers expect excellent FDA results confirming much higher prices in the vicinity of $100.

I do.

Inovio intends to use the net proceeds from the offering for general corporate purposes, including clinical trial expenses, research and development expenses, general and administrative expenses and manufacturing expenses, and for other business development activities.

Partners and collaborators include MedImmune, Regeneron, Roche/Genentech, ApolloBio Corporation, The Wistar Institute, The Bill & Melinda Gates Foundation, the University of Pennsylvania, Parker Institute for Cancer Immunotherapy, CEPI, DARPA, GeneOne Life Science, Plumbline Life Sciences, Drexel University, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, and Laval University.

https://ih.advfn.com/stock-market/NASDAQ/inovio-pharmaceuticals-inc-INO/stock-news/79264924/inovio-pharmaceuticals-prices-65-0-million-conver

Renewlogy gets nod for Phoenix mixed-plastics program

Posted on February 13, 2019

by Colin Staub

A city of Phoenix evaluation team is recommending plastics-to-fuel company Renewlogy be selected to operate a diversion program recovering post-consumer No. 3-7 plastics.

The Arizona metropolis of more than 1.6 million residents last summer asked companies to submit proposals to process the city’s mixed plastics. As reported by Plastics Recycling Update, the city’s Public Works department solicitation sought companies using “waste-to-product or waste-to-liquid fuel technologies.”

https://resource-recycling.com/plastics/2019/02/13/renewlogy-gets-nod-for-phoenix-mixed-plastics-program/
https://renewlogy.com/

I love to watch an Amazon birth.

And pigs that fly.

Pigs might fly, too.

https://ih.advfn.com/p.php?pid=nmona&article=79112670

Dynomite!

Money will decide the issue.

And China will prevail!

Money talks.

Electric rules.

To the Victor in competition goes the spoils.

SEDAR is closed for maintenance today but open tomorow:

https://www.sedar.com/search/search_en.htm
https://www.sedar.com/search/search_form_pc_en.htm

https://www.sedar.com/DisplayCompanyDocuments.do?lang=EN&issuerNo=00006073

Nano One + Saint-Gobain:

https://www.siliconinvestor.com/readmsg.aspx?msgid=31986568